Investigational drug · Phase 2
SI-B003
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
11
Any phase or sponsor naming "SI-B003"
First trial start
2023
Feb 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SI-B003", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Nasopharyngeal Carcinoma
- Esophageal Cancer
- Gastric Cancer
- Colorectal Cancer
- Urothelial Carcinoma
- Solid Tumor
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SI-B003" as an intervention, largest first.
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06008054 · 376 participants (planned) · Start Nov 16, 2023 · Primary completion Dec 2026
Drug: SI-B003; BL-B01D1 and 1 more · For: Esophageal Cancer; Gastric Cancer; Colorectal Cancer
Sites: Beijing, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06006169 · 186 participants (planned) · Start Oct 20, 2023 · Primary completion Dec 2026
Drug: BL-B01D1; SI-B003 · For: Head and Neck Squamous Cell Carcinoma
Sites: Shanghai, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05990803 · 130 participants (planned) · Start Nov 6, 2023 · Primary completion Dec 2026
Drug: BL-B01D1; SI-B003 · For: Cervical Cancer
Sites: Beijing, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05956587 · 121 participants (planned) · Start Jan 29, 2024 · Primary completion Dec 2026
Drug: BL-B01D1; SI-B003 · For: Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma
Sites: Chongqing, China; Fuzhou, China; Guangzhou, China · 16 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05924841 · 100 participants (planned) · Start Nov 10, 2023 · Primary completion Dec 2026
Drug: BL-B01D1; SI-B003 · For: Small Cell Lung Cancer
Sites: Changchun, China
- A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05949606 · 95 participants · Start Oct 30, 2023 · Primary completion Dec 2026
Drug: SI-B001; SI-B003 · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05668858 · 70 participants · Start Feb 10, 2023 · Primary completion Dec 2026
Drug: SI-B001; SI-B003 · For: Squamous Cell Carcinoma of Head and Neck
Sites: Shanghai, China
- A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT04606472 · 60 participants · Start Nov 10, 2020 · Primary completion Dec 2025
Drug: SI-B003 · For: Solid Tumor
Sites: Beijing, China; Chongqing, China; Xiamen, China · 8 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06042894 · 58 participants (planned) · Start Dec 12, 2023 · Primary completion Dec 2026
Drug: BL-B01D1; SI-B003 · For: Breast Cancer
Sites: Shanghai, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05965856 · 52 participants (planned) · Start Dec 11, 2023 · Primary completion Dec 2026
Drug: BL-B01D1; SI-B003 · For: Urothelial Carcinoma; Solid Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.